FGEN FibroGen Inc

38.86
+0.83  (+2%)
Previous Close 38.03
Open 38
Price To Book 5.37
Market Cap 3,377,555,605
Shares 86,915,996
Volume 427,726
Short Ratio
Av. Daily Volume 595,249
Stock charts supplied by TradingView

NewsSee all news

  1. Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019

    SAN FRANCISCO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced that results from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology

  2. FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine

    SAN FRANCISCO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) is pleased to announce that William G. Kaelin, Jr., who serves on the company's Scientific Advisory Board, has been awarded the 2019 Nobel

  3. FibroGen Receives One of China Pharmaceutical Industry's Highest Awards for Clinical Innovation for Roxadustat

    SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that roxadustat received the 2019 Dushu Lake Prize 独墅湖杯in China for "On-Market Innovative Drug with Highest Clinical

  4. FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis

    -- Novel Human Antibody Targets CTGF, A Central Mediator in Fibrosis -- SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced publication in The Lancet Respiratory Medicine of

  5. FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy

    SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced first patient dosed in the company's Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA filing due October 2019.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 data due 2H 2020.
Roxadustat
Myelodysplastic syndromes (MDS)
Phase 2 detailed data due 2H 2019.
FG-3019
Duchenne muscular dystrophy
Phase 2 ongoing in Hong Kong. Future development uncertain
FG-3019
Liver fibrosis
Phase 3 trial initiation announced July 22, 2019.
Pamrevlumab (FG-3019) - ZEPHYRUS
Idiopathic pulmonary fibrosis
Phase 3 trial to be initiated 2Q 2019.
Pamrevlumab (FG-3019)
Pancreatic cancer
Phase 3 Japan data noted hepcidin reduction from baseline (p=0.003) compared to epoetin alfa group (p=0.12)
Roxadustat
Chronic kidney disease
Phase 2 trial initiation announced September 26, 2019.
Roxadustat
Chemotherapy-induced anemia (CIA)

Latest News

  1. Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019

    SAN FRANCISCO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), today announced that results from the global Phase 3 roxadustat clinical program will be presented at the American Society of Nephrology

  2. FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine

    SAN FRANCISCO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) is pleased to announce that William G. Kaelin, Jr., who serves on the company's Scientific Advisory Board, has been awarded the 2019 Nobel

  3. FibroGen Receives One of China Pharmaceutical Industry's Highest Awards for Clinical Innovation for Roxadustat

    SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced that roxadustat received the 2019 Dushu Lake Prize 独墅湖杯in China for "On-Market Innovative Drug with Highest Clinical

  4. FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis

    -- Novel Human Antibody Targets CTGF, A Central Mediator in Fibrosis -- SAN FRANCISCO, Sept. 30, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced publication in The Lancet Respiratory Medicine of

  5. FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy

    SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) today announced first patient dosed in the company's Phase 2 clinical study of roxadustat, a first-in-class hypoxia-inducible factor prolyl

  6. Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

    SAN FRANCISCO and TOKYO, Sept. 20, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN, Interim CEO: James A. Schoeneck, "FibroGen")) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D.,

  7. Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients

    TOKYO and SAN FRANCISCO, Sept. 20, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and FibroGen, Inc. (NASDAQ:FGEN, Interim CEO: James A Schoeneck.,

  8. Fibrogen Announces Passing of CEO Thomas B. Neff, Scientific Innovator and Pioneering Biopharmaceutical Executive

    SAN FRANCISCO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced today that Thomas B. Neff, Chief Executive Officer and Chairman of the Board of Directors of FibroGen, passed away unexpectedly